Loading...

NRIX NURIX THERAPEUTICS INC Expansion Plans 8-K Filing

NRX

NRX

NURIX THERAPEUTICS INC

(NRIX)

2025 8-K

Annual Meeting Results

Financial Results Update

Equity Offering Update

Financial Results

Conference Presentation

Clinical Data Update

Director Appointment

Share Offering Alert

Clinical Trial Launch

Financial Results Update

Investor Meetings

Director Resignation

Financial Statements

New Product Launches

Financial Results

Director Appointment

Financial Results

Financial Update

Clinical Data Update

Director Appointment

Financial Results

Investor Meetings

Financial Results and Equit...

Clinical Trial Data Update

Annual Meeting of Stockholders

Agreement for Stock and War...

Financial Results Announcement

Clinical Trial Results

Other Special Situation

Financial Results Announcement

Regulation FD Disclosure

Investor Conferences

Other Special Situation

Financial Results Announcement

Annual Meeting of Stockholders

Financial Results Announcement

SVB Receivership

Financial Results Announcement

Presentation and Press Release

External Links:

On October 22, 2025, Nurix Therapeutics, Inc. announced the start of the DAYBreak clinical trial for its drug bexobrutideg (NX-5948), aimed at treating patients with chronic lymphocytic leukemia. The pivotal Phase 2 study will enroll around 100 patients to assess the drug's effectiveness after previous treatments have failed.

AI Assistant

NURIX THERAPEUTICS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.